Cyclopropavir inhibits the normal function of the human cytomegalovirus UL97 kinase

Antimicrobial Agents and Chemotherapy

Volumn 55, Issue 10, 2011, Pages 4682-4691

  James, Scott H ^a   Hartline, Caroll B ^a   Harden, Emma A ^a   Driebe, Elizabeth M ^b   Schupp, James M ^b   Engelthaler, David M ^b   Keim, Paul S ^b,c   Bowlin, Terry L ^d   Kern, Earl R ^a   Prichard, Mark N ^a  

^a University of Alabama at Birmingham   (United States)

^b TRANSLATIONAL GENOMICS RESEARCH INSTITUTE   (United States)

^c NORTHERN ARIZONA UNIVERSITY   (United States)

^d MICROBIOTIX INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIVIRUS AGENT; BENZIMIDAVIR; CYCLOPROPAVIR; GANCICLOVIR; UL97 KINASE; UNCLASSIFIED DRUG; VIRUS ENZYME;

ANTIVIRAL ACTIVITY; ARTICLE; CELL CULTURE; CELL STRUCTURE; CONTROLLED STUDY; CYTOTOXICITY; DNA SYNTHESIS; DRUG ANTAGONISM; ENZYME ACTIVITY; ENZYME INHIBITION; FIBROBLAST; FRAMESHIFT MUTATION; HUMAN; HUMAN CELL; HUMAN CYTOMEGALOVIRUS; NONHUMAN; PRIORITY JOURNAL; REAL TIME POLYMERASE CHAIN REACTION;

ANIMALS; ANTIVIRAL AGENTS; BASE SEQUENCE; BENZIMIDAZOLES; CELL LINE; CERCOPITHECUS AETHIOPS; COS CELLS; CYCLOPROPANES; CYTOMEGALOVIRUS; DNA, VIRAL; DRUG RESISTANCE, VIRAL; FRAMESHIFT MUTATION; GANCICLOVIR; GUANINE; HERPESVIRUS 6, HUMAN; HERPESVIRUS 8, HUMAN; HIGH-THROUGHPUT NUCLEOTIDE SEQUENCING; HUMANS; PHOSPHOTRANSFERASES (ALCOHOL GROUP ACCEPTOR); RIBONUCLEOSIDES; SEQUENCE ANALYSIS, DNA;

EID: 80052869461     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.00571-11     Document Type: Article

References (43)

1. Andrei, G., E. De Clercq, and R. Snoeck. 2009. Drug targets in cytomegalovirus infection. Infect. Disord. Drug Targets 9:201-222.
2. Biron, K. K. 2006. Antiviral drugs for cytomegalovirus diseases. Antiviral Res. 71:154-163. (Pubitemid 44223768)
3. Biron, K. K., et al. 2002. Potent and selective inhibition of human cytomegalovirus replication by 1263W94, a benzimidazole L-riboside with a unique mode of action. Antimicrob. Agents Chemother. 46:2365-2372.
4. Boppana, S. B., K. B. Fowler, W. J. Britt, S. Stagno, and R. F. Pass. 1999. Symptomatic congenital cytomegalovirus infection in infants born to mothers with preexisting immunity to cytomegalovirus. Pediatrics 104:55-60.
5. Chou, S. 2008. Cytomegalovirus UL97 mutations in the era of ganciclovir and maribavir. Rev. Med. Virol. 18:233-246.
6. Chou, S. 2009. Diverse cytomegalovirus UL27 mutations adapt to loss of viral UL97 kinase activity under maribavir. Antimicrob. Agents Chemother. 53:81-85.
7. Chou, S., and T. L. Bowlin. 2011. Cytomegalovirus UL97 mutations affecting cyclopropavir and ganciclovir susceptibility. Antimicrob. Agents Chemother. 55:382-384.
8. Chou, S., and G. I. Marousek. 2006. Maribavir antagonizes the antiviral action of ganciclovir on human cytomegalovirus. Antimicrob. Agents Chemother. 50:3470-3472.
9. Duval, X., et al. 2010. Efficacy of oseltamivir-zanamivir combination compared to each monotherapy for seasonal influenza: a randomized placebo-controlled trial. PLoS Med. 7:e1000362.
10. Gentry, B. G., S. N. Gentry, T. L. Jackson, J. Zemlicka, and J. C. Drach. 2011. Phosphorylation of antiviral and endogenous nucleotides to di- and triphosphates by GMP kinase. Biochem. Pharmacol. 81:43-49.
11. Gentry, B. G., J. P. Kamil, D. M. Coen, J. Zemlicka, and J. C. Drach. 2010. Stereoselective phosphorylation of cyclopropavir by pUL97 and competitive inhibition by maribavir. Antimicrob. Agents Chemother. 54:3093-3098.
12. Gilbert, C., J. Bestman-Smith, and G. Boivin. 2002. Resistance of herpesviruses to antiviral drugs: clinical impacts and molecular mechanisms. Drug Resist. Updat. 5:88-114.
13. Gilbert, C., and G. Boivin. 2005. Human cytomegalovirus resistance to antiviral drugs. Antimicrob. Agents Chemother. 49:873-883.
14. Gill, R. B., S. L. Frederick, C. B. Hartline, S. Chou, and M. N. Prichard. 2009. Conserved retinoblastoma protein-binding motif in human cytomegalovirus UL97 kinase minimally impacts viral replication but affects susceptibility to maribavir. Virol. J. 6:9.
15. Griffiths, P. D. 2001. Cytomegalovirus therapy: current constraints and future opportunities. Curr. Opin. Infect. Dis. 14:765-768.
16. Kern, E. R., et al. 2004. Oral activity of a methylenecyclopropane analog, cyclopropavir, in animal models for cytomegalovirus infections. Antimicrob. Agents Chemother. 48:4745-4753.
17. Kern, E. R., et al. 2005. In vitro activity and mechanism of action of methylenecyclopropane analogs of nucleosides against herpesvirus replication. Antimicrob. Agents Chemother. 49:1039-1045.
18. Kimberlin, D. W., et al. 2003. Effect of ganciclovir therapy on hearing in symptomatic congenital cytomegalovirus disease involving the central nervous system: a randomized, controlled trial. J. Pediatr. 143:16-25. (Pubitemid 36928564)
19. Li, C., B. G. Gentry, J. C. Drach, and J. Zemlicka. 2009. Synthesis and enantioselectivity of cyclopropavir phosphates for cellular GMP kinase. Nucleosides Nucleotides Nucleic Acids 28:795-808.
20. Li, C., M. N. Prichard, B. E. Korba, J. C. Drach, and J. Zemlicka. 2008. Fluorinated methylenecyclopropane analogues of nucleosides. Synthesis and antiviral activity of (Z)- and (E)-9-{[(2-fluoromethyl-2-hydroxymethyl)- cyclopropylidene]methyl}adenine and -guanine. Bioorg. Med. Chem. 16: 2148-2155.
21. Lurain, N. S., and S. Chou. 2010. Antiviral drug resistance of human cytomegalovirus. Clin. Microbiol. Rev. 23:689-712.
22. Mhaske, S. B., B. Ksebati, M. N. Prichard, J. C. Drach, and J. Zemlicka. 2009. Phosphonate analogues of cyclopropavir phosphates and their E-isomers. Synthesis and antiviral activity. Bioorg. Med. Chem. 17:3892-3899.
23. Morton, C. C., and W. E. Nance. 2006. Newborn hearing screening - a silent revolution. N. Engl. J. Med. 354:2151-2164.
24. Nassetta, L., D. Kimberlin, and R. Whitley. 2009. Treatment of congenital cytomegalovirus infection: implications for future therapeutic strategies. J. Antimicrob. Chemother. 63:862-867.
25. Nguyen, J. T., et al. 2010. Triple combination of amantadine, ribavirin, and oseltamivir is highly active and synergistic against drug resistant influenza virus strains in vitro. PLoS One 5:e9332.
26. Nguyen, J. T., et al. 2009. Triple combination of oseltamivir, amantadine, and ribavirin displays synergistic activity against multiple influenza virus strains in vitro. Antimicrob. Agents Chemother. 53:4115-4126.
27. Prichard, M. N., W. J. Britt, S. L. Daily, C. B. Hartline, and E. R. Kern. 2005. Human cytomegalovirus UL97 kinase is required for the normal intranuclear distribution of pp65 and virion morphogenesis. J. Virol. 79:15494-15502.
28. Prichard, M. N., S. L. Daily, G. M. Jefferson, A. L. Perry, and E. R. Kern. 2007. A rapid DNA hybridization assay for the evaluation of antiviral compounds against Epstein-Barr virus. J. Virol. Methods 144:86-90.
29. Prichard, M. N., et al. 1999. A recombinant human cytomegalovirus with a large deletion in UL97 has a severe replication deficiency. J. Virol. 73:5663-5670. (Pubitemid 29274851)
30. Prichard, M. N., K. A. Keith, D. C. Quenelle, and E. R. Kern. 2006. Activity and mechanism of action of N-methanocarbathymidine against herpesvirus and orthopoxvirus infections. Antimicrob. Agents Chemother. 50:1336-1341.
31. Prichard, M. N., E. R. Kern, C. B. Hartline, R. Lanier, and D. C. Quenelle. 25 July 2011, posting date. CMX001 potentiates the efficacy of acyclovir in herpes simplex virus infections. Antimicrob. Agents Chemother. [Epub ahead of print.] doi:10.1128/AAC.00545-11.
32. Prichard, M. N., et al. 2009. Inhibition of herpesvirus replication by 5-substituted 4′-thiopyrimidine nucleosides. Antimicrob. Agents Chemother. 53:5251-5258.
33. Prichard, M. N., and C. Shipman, Jr. 1990. A three-dimensional model to analyze drug-drug interactions. Antiviral Res. 14:181-205. (Pubitemid 20377558)
34. Prichard, M. N., et al. 2008. Human cytomegalovirus UL97 kinase activity is required for the hyperphosphorylation of retinoblastoma protein and inhibits the formation of nuclear aggresomes. J. Virol. 82:5054-5067. (Pubitemid 351657065)
35. Reitsma, J. M., et al. 2011. Antiviral inhibition targeting the HCMV kinase pUL97 requires pUL27-dependent degradation of Tip60 acetyltransferase and cell-cycle arrest. Cell Host Microbe 9:103-114.
36. Ross, S. A., et al. 2006. Hearing loss in children with congenital cytomegalovirus infection born to mothers with preexisting immunity. J. Pediatr. 148:332-336.
37. Strippoli, G. F., E. M. Hodson, C. Jones, and J. C. Craig. 2006. Preemptive treatment for cytomegalovirus viremia to prevent cytomegalovirus disease in solid organ transplant recipients. Transplantation 81:139-145.
38. Torres-Madriz, G., and H. W. Boucher. 2008. Immunocompromised hosts: perspectives in the treatment and prophylaxis of cytomegalovirus disease in solid-organ transplant recipients. Clin. Infect. Dis. 47:702-711.
39. Williams-Aziz, S. L., et al. 2005. Comparative activities of lipid esters of cidofovir and cyclic cidofovir against replication of herpesviruses in vitro. Antimicrob. Agents Chemother. 49:3724-3733.
40. Zhou, S., J. C. Drach, M. N. Prichard, and J. Zemlicka. 2009. (Z)- and (E)-2-(1,2-dihydroxyethyl)methylenecyclopropane analogues of 2′-deoxyadenosine and 2′-deoxyguanosine. Synthesis of all stereoisomers, absolute configuration, and antiviral activity. J. Med. Chem. 52:3397-3407.
41. Zhou, S., et al. 2004. (Z)- and (E)-[2-Fluoro-2-(hydroxymethyl) cyclopropylidene] methylpurines and -pyrimidines, a new class of methylenecyclopropane analogues of nucleosides: synthesis and antiviral activity. J. Med. Chem. 47:6964-6972.
42. Zhou, S., and J. Zemlicka. 2007. Synthesis of 2,2,3-tris(hydroxymethyl) methylenecyclopropane analogues of nucleosides. Nucleosides Nucleotides Nucleic Acids 26:391-402.
43. Zhou, S., J. Zemlicka, E. R. Kern, and J. C. Drach. 2007. Fluoroanalogues of anti-cytomegalovirus agent cyclopropavir: synthesis and antiviral activity of (E)- and (Z)-9-{[2,2-bis(hydroxymethyl)-3-fluorocyclopropylidene] methyl}-adenines and guanines. Nucleosides Nucleotides Nucleic Acids 26:231-243.